A combination of two drugs shows promise in treating a rare and therapy-resistant type of melanoma that originates in the eye and spreads to other organs, according to a new study led by Duke University Comprehensive Cancer Center researchers. ...
Source:
Duke University Medical Center
Tuesday, September 4, 2007